RBC Capital Initiates Coverage On Contineum Therapeutics with Outperform Rating, Announces Price Target of $30
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams initiates coverage on Contineum Therapeutics (NASDAQ:CTNM) with an Outperform rating and a price target of $30.

April 30, 2024 | 9:44 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Contineum Therapeutics receives an Outperform rating from RBC Capital with a price target of $30.
The initiation of coverage by RBC Capital with an Outperform rating and a high price target of $30 is likely to generate positive investor sentiment towards Contineum Therapeutics. This endorsement from a reputable analyst could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100